Literature DB >> 21188534

Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells.

Fan Lin1, Yuyuan Li, Jie Cao, Shaofeng Fan, Jifeng Wen, Guanghui Zhu, Hong Du, Yanxiao Liang.   

Abstract

Osteopontin (OPN) plays an important role in metastasis and relapse of human cancer. However, the whole story of OPN relating to cancer has been far from clear untill now. To investigate the expression of OPN in hepatocellular carcinoma (HCC) and its relationships with recurrence and metastasis of HCC, normal and malignant liver tissues from patients with HCC were analyzed using immunohistochemical staining. OPN expression was inhibited by small interfering RNA (siRNA) in HCC cells lines, and then colony formation and matrigel invasion were examined. The results showed that expression of OPN was associated with metastasis of HCC with a positive rate of OPN in the tissue of HCC (70.00%), which was highly more obvious than those in paracarcinoma tissue and normal liver tissue (P < 0.01). In HCC cell lines, OPN depletion could reduce formed colony and metastasizing numbers in vitro. In conclusion, Expression of OPN in the tissue of HCC is related to metastasis or metastases. Specific siRNA could decrease expressions of OPN at both mRNA and protein levels, and abates the invasiveness of hepatocellular carcinoma cells, suggesting that OPN might be a promising agent for treatment of metastasis and recurrence of HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21188534     DOI: 10.1007/s11033-010-0671-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  23 in total

1.  Osteopontin as a biomarker for ovarian cancer.

Authors:  Anthony O'Regan; Catherine Fleming
Journal:  JAMA       Date:  2002-06-26       Impact factor: 56.272

2.  Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis.

Authors:  Thorsten Graef; Ulrich Steidl; Wolfgang Nedbal; Ulrich Rohr; Roland Fenk; Rainer Haas; Ralf Kronenwett
Journal:  Angiogenesis       Date:  2006-01-07       Impact factor: 9.596

3.  Co-expression of osteopontin and CD44v9 in gastric cancer.

Authors:  T Ue; H Yokozaki; Y Kitadai; S Yamamoto; W Yasui; T Ishikawa; E Tahara
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

4.  Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness.

Authors:  Angela Celetti; Domenico Testa; Stefania Staibano; Francesco Merolla; Valentina Guarino; Maria Domenica Castellone; Renata Iovine; Gelsomina Mansueto; Pasquale Somma; Gaetano De Rosa; Vieri Galli; Rosa Marina Melillo; Massimo Santoro
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

5.  Hepatic blood inflow occlusion with/without hemihepatic artery control versus the Pringle maneuver in resection of hepatocellular carcinoma: a retrospective comparative analysis.

Authors:  Bin Yi; Ying-he Qiu; Chen Liu; Xiang-ji Luo; Xiao-qing Jiang; Wei-feng Tan; Meng-chao Wu
Journal:  Chin Med J (Engl)       Date:  2010-06       Impact factor: 2.628

6.  The osteopontin gene +1239A/C single nucleotide polymorphism is associated with type 1 diabetes mellitus in the Italian population.

Authors:  A Chiocchetti; E Orilieri; G Cappellano; N Barizzone; S D' Alfonso; G D' Annunzio; R Lorini; R Ravazzolo; F Cadario; M Martinetti; V Calcaterra; F Cerutti; G Bruno; D Larizza; U Dianzani
Journal:  Int J Immunopathol Pharmacol       Date:  2010 Jan-Mar       Impact factor: 3.219

Review 7.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

8.  Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer.

Authors:  Suzete de Silva Rudland; Lee Martin; Chandeene Roshanlall; John Winstanley; Samuel Leinster; Angela Platt-Higgins; Joe Carroll; Christopher West; Roger Barraclough; Philip Rudland
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

Review 9.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

10.  Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells.

Authors:  Alessandro Salvi; Bruna Arici; Giuseppina De Petro; Sergio Barlati
Journal:  Mol Cancer Ther       Date:  2004-06       Impact factor: 6.261

View more
  15 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

Review 2.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.

Authors:  Wing-Kin Syn; Kolade M Agboola; Marzena Swiderska; Gregory A Michelotti; Evaggelia Liaskou; Herbert Pang; Guanhua Xie; George Philips; Isaac S Chan; Gamze F Karaca; Thiago de Almeida Pereira; Yuping Chen; Zhiyong Mi; Paul C Kuo; Steve S Choi; Cynthia D Guy; Manal F Abdelmalek; Anna Mae Diehl
Journal:  Gut       Date:  2012-03-17       Impact factor: 23.059

Review 4.  Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Nai-Kong V Cheung
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

5.  A preliminary in vivo study of the effects of OPN on rat liver regeneration induced by partial hepatectomy.

Authors:  Gaiping Wang; Congcong Zhao; Shasha Chen; Xiaofang Li; Ling Zhang; Cuifang Chang; Cunshuan Xu
Journal:  Mol Biol Rep       Date:  2016-09-01       Impact factor: 2.316

Review 6.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

Review 7.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

8.  Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients.

Authors:  Yue Qiu; Yuan Hu; Zuo-Yang Zhang; Lei Ye; Fei-Hong Xu; Marion E Schneider; Xue-Ling Ma; Yi-Xin Du; Xian-Bo Zuo; Fu-Sheng Zhou; Gang Chen; Xu-Shi Xie; Yan Zhang; Hong-Zhen Xia; Ji-Feng Wu; Wei-Dong Du
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-10       Impact factor: 4.553

Review 9.  MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells.

Authors:  Amir Sadra Zangouei; Maliheh Alimardani; Meysam Moghbeli
Journal:  Cancer Cell Int       Date:  2021-04-15       Impact factor: 5.722

10.  Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice.

Authors:  Fan Lin; Jie Cao; Zhiming Huang; Zhenghao Pei; Weili Gu; Shaofeng Fan; Kunping Li; Jiefeng Weng
Journal:  Exp Ther Med       Date:  2013-03-15       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.